Loading startup
Market data is refreshed once per day from public sources. Information may be incomplete or outdated — verify independently before making decisions. This is not investment advice.
Evidence-bound summary — expand sections for movement, risks, and signals.
Memo snapshot · May 20, 2026, 6:27 PM
What would change this read
DealFlow OS uses public web data and automated enrichment. Research may be incomplete, outdated, or incorrect. Verify important information before making investment or outreach decisions.
TL;DR
Seed (YC)Ruma Care Prior auth automation for infusion clinics.
Latest: Seed. Investors: Y Combinator. (High).
Funding
Latest: Seed. Investors: Y Combinator. (High).
Product / news
2 product/news‑styled row(s); headline risk without filings (High).
Verified facts
Winter 2026 batch; AI prior authorizations for biologic infusion clinics.
Weak funding evidence: mention does not include a parsed raise amount/round and may refer to non-funding context.
No open roles indexed yet.
The index price and activity score are algorithmic estimates based on observed public company-level signals. They may be incomplete, stale, or inaccurate and are not investment, legal, tax, or business advice.
Source types found
Strongest / recent news-style rows
Wed, May 20, 06:27 PM · confidence 88%high quality
wikipedia · Mon, Jun 29, 11:07 AM · confidence 50%medium quality
Wed, May 20, 06:27 PM · confidence 85%medium quality
Newest first · 6 event(s)
Source: Homepage
We help clinics get patients on biologics faster | AI prior authorizations for buy and bill and infusions
Source: Blog / news
We help clinics get patients on biologics faster | AI prior authorizations for buy and bill and infusions
Winter 2026 batch; AI prior authorizations for biologic infusion clinics.
YC launch on biologic prior authorizations.
1 row(s)
The company's own site — the authoritative description of what they sell and to whom. Marketing-controlled, so treat claims as positioning rather than verified traction.
We help clinics get patients on biologics faster | AI prior authorizations for buy and bill and infusions
Why it matters: Primary source — the company's own positioning; best read for what they sell and to whom, not for traction claims.
Open source ↗3 row(s)
Third-party press coverage. Independent reporting corroborates company claims; repeated coverage across outlets is a momentum signal.
Why it matters: Independent coverage — third-party corroboration of company claims; recurring coverage indicates rising visibility.
Open source ↗YC launch on biologic prior authorizations.
Why it matters: Independent coverage — third-party corroboration of company claims; recurring coverage indicates rising visibility.
Open source ↗Why it matters: Independent coverage — third-party corroboration of company claims; recurring coverage indicates rising visibility.
Open source ↗1 row(s)
Funding announcements and investor-database records. The strongest public signal of capitalization: round, amount, and syndicate quality when disclosed.
Winter 2026 batch; AI prior authorizations for biologic infusion clinics.
Why it matters: Funding signal — Seed per this source; verify against the linked original before relying on it.
Open source ↗1 row(s)
Company blog and newsletters. Shipping cadence and technical depth of posts hint at product velocity and team quality.
We help clinics get patients on biologics faster | AI prior authorizations for buy and bill and infusions
Why it matters: Company publishing — post cadence and depth hint at product velocity.
Open source ↗Sign in as an active team member to view private notes, watchlist controls, transcript evidence, and interaction history.